Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.

Abstract

AIMS:

This study aimed to evaluate the incidence and prevalence of blindness, sight impairment, and other visual acuity (VA) states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire.

METHODS:

Serial VA and injection data for all treatment-naive patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008 and 2010 were extracted from an electronic medical record system.

RESULTS:

The prevalence of blindness (VA in the better-seeing eye ≤25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after 3 years. The prevalence of sight impairment (VA in the better-seeing eye 26-39 ETDRS letters) increased from 4.1% at baseline to 5.5% after 3 years. The incidence of initiating ranibizumab treatment for nAMD in people aged ≥50 years in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of patients meeting the visual criteria for blindness and sight impairment registration from treated nAMD in people aged ≥50 years in Gloucestershire was 3.5 and 9.7 people, respectively per 100 000 population in 2010.

CONCLUSION:

This is the first real-world study on the incidence and prevalence of eligibility for blindness and sight impairment registration in treated nAMD in the UK based on VA data. The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.

• Authors: M Buckle, A Lee, Q Mohamed, E Fletcher, A Sallam, R Healy, I Stratton, A Tufail, R L Johnston
• Journal: Eye (London, England) (Eye (Lond)) Vol. 29 Issue 3 Pg. 403-8 (Mar 2015) ISSN: 1476-5454 [Electronic] England
• PMID: 25592123 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Blindness (epidemiology)
• Female
• Humans
• Incidence
• Intravitreal Injections
• Male
• Middle Aged
• Prevalence
• Prospective Studies
• Ranibizumab
• Registries
• United Kingdom (epidemiology)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Vision, Low (epidemiology)
• Visual Acuity
• Visually Impaired Persons (statistics & numerical data)
• Wet Macular Degeneration (drug therapy, epidemiology)